What is Complix?
Complix is a biopharmaceutical company specializing in the development of transformative Cell Penetrating Alphabody (CPAB) therapeutics aimed at addressing challenging intracellular targets associated with life-threatening diseases, particularly cancer and autoimmune disorders. Their proprietary technology allows for the targeting of previously undruggable disease targets and offers innovative delivery methods, including non-injectable options. Complix is actively developing a pipeline of product candidates and seeks partnerships to enhance the potential of its Alphabody platform. The company is committed to creating novel therapeutic interventions that expand the reach of biopharmaceuticals beyond traditional limitations. The company's journey, marked by distinct funding stages from Series A to Series B, indicates a progression from early-stage development to scaling its operations and therapeutic pipeline.
How much funding has Complix raised?
Complix has raised a total of $22.3M across 3 funding rounds:
Series A
$6.2M
Series B
$15.5M
Grant
$600K
Series A (2010): $6.2M with participation from Lrm, CRP Sante, and Vesalius Biocapital Partners
Series B (2013): $15.5M led by OMNES Capital, CRP-Sante, Baekeland Fund, Vesalius Biocapital Partners, Edmond de Rothschild Investment Partners, TrustCapital, and Gimv
Grant (2017): $600K, investors not publicly disclosed
Key Investors in Complix
Lrm
LRM is a venture capital provider that supports economic development and innovation in Limburg by offering smart money and managing business campuses and incubators. The company focuses on collaboration with various stakeholders to create impactful networks that foster sustainable growth and innovation.
CRP Sante
CRP-Santé is a company that operates in the Research & Development industry, headquartered in Luxembourg, Luxembourg. It focuses on R&D initiatives within the health sector.
Vesalius Biocapital Partners
Vesalius Biocapital Partners Sàrl is a venture capital firm that invests in innovative European life science companies, particularly favoring early-stage projects with strong proprietary technology and unique team skills.
What's next for Complix?
With its recent major strategic investment, Complix is poised to further its mission of developing novel therapeutic interventions. The company's focus on targeting previously undruggable intracellular disease targets, particularly in oncology and autoimmune disorders, positions it at the forefront of biopharmaceutical innovation. The infusion of capital will likely fuel the advancement of its CPAB pipeline, potentially leading to new clinical trials and strategic partnerships. Complix's commitment to exploring non-injectable delivery methods also suggests a forward-thinking approach to patient accessibility and therapeutic efficacy, aiming to redefine the boundaries of biopharmaceutical development.
See full Complix company page
